April 1, 2021 -- Scribe Therapeutics has raised $100 million in financing, which will be used to further develop its suite of custom gene editing and delivery technologies, as well as advance a pipeline of therapeutics for neurodegeneration and other diseases with high unmet need.
Scribe is developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company will continue to develop additional technologies to add to its integrated platform, it said.
"Scribe's engineering-first philosophy has resulted in a uniquely flexible platform for imagining and creating a new era of CRISPR-based therapies to elevate the standard of care for thousands of patients," said Jennifer Doudna, PhD, co-inventor of CRISPR technology, Nobel Laureate, and cofounder of Scribe Therapeutics.
The series B financing was led by Avoro Ventures and Avoro Capital Advisors. As part of the financing, Behzad Aghazadeh, managing partner at Avoro Ventures and Avoro Capital Advisors, and Carl Gordon, managing partner at OrbiMed Advisors, will join Scribe's Board of Directors.